CommercialCoverageLow impact
08.01.28e, Sebelipase alfa (Kanuma®)
Independence Blue Cross·Endocrinology, Gastroenterology, Pediatrics·Pharmacy
Effective date
Sep 3, 2025
We identified it
Jun 19, 2026
Summary
A commercial policy for Sebelipase alfa (Kanuma®), a specialty pharmacy medication, has been reissued and will become effective on September 3, 2025. This appears to be a routine policy update or clarification for this rare disease medication used to treat lysosomal acid lipase deficiency.
Action Required
By September 3, 2025: Billing team should review the updated policy details at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Sebelipase alfa (Kanuma®). Update any relevant billing protocols if changes are identified in the full policy document.